Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucantime plus topical paromomycin for cutaneous leishmaniasis caused by Leishmania tropica
IRCT138904241475N5Phase 3Completed
- Sponsor
- World Health Organization
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of meglumine antimoniate and paromomycin in cutaneous leishmaniasis (CL) (2 arms), sponsored by World Health Organization. Started Apr 2011; status: completed.
02
Drugs
meglumine antimoniateparomomycin
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT138904241475N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT138904241475N5.